1. Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2). (4th March 2020) Authors: Maggiolo, F; Gianotti, N; Comi, L; Di Filippo, E; Fumagalli, L; Nozza, S; Galli, L; Valenti, D; Rizzi, M; Castagna, A Journal: Journal of antimicrobial chemotherapy Issue: Volume 75:Number 5(2020) Page Start: 1332 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗